Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells
- 1 January 2016
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 497 (1-2) , 78-87
Abstract
No abstract availableKeywords
Funding Information
- Central Lab of General Biology, Jilin University, China
This publication has 35 references indexed in Scilit:
- A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug deliveryBiomaterials, 2010
- Retraction notice to ``Enhanced Antiproliferative Activity of Carboplatin loaded Chitosan-Alginate Nanoparticles in Retinoblastoma Cell Line’’ [Acta Biomaterialia 6 (2010) 3120–3131]Acta Biomaterialia, 2010
- PLGA–lecithin–PEG core–shell nanoparticles for controlled drug deliveryBiomaterials, 2009
- The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticlesBiomaterials, 2009
- Retargeting of adenoviral gene delivery via Herceptin–PEG–adenovirus conjugates to breast cancer cellsJournal of Controlled Release, 2007
- Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles☆Advanced Drug Delivery Reviews, 2007
- Encapsulation of dexamethasone into biodegradable polymeric nanoparticlesInternational Journal of Pharmaceutics, 2007
- Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activationExperimental Cell Research, 2005
- Targeted prodrug treatment of HER‐2‐positive breast tumor cells using trastuzumab and paclitaxel linked by A‐Z‐CINNTM LinkerJournal of Experimental Therapeutics and Oncology, 2003
- A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UKEuropean Journal of Cancer, 2001